Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

First, a point of personal pride.  The Blunt Truth started in February 2016, with the slightly crazy idea that a BigLaw firm could talk about marijuana on a regular basis.  As of this week, we’ve

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Let’s start, as we so often do, with the states.   Nebraska has decided against legalizing medical marijuana.  Texas is moving towards legalizing hemp.  Iowa is one step ahead of them – hemp cultivation will begin in

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

The big news this week was the re-introduction of the STATES Act.  The bill would protect marijuana businesses and consumers in states where it is legal, and in what is a rarity in our increasingly partisan

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Our weekly review starts in Georgia, where the governor is expected to sign a medical marijuana reform bill into law.  The law will allow grow houses and production facilities in the state, which will be heavily

This is Washington, and we do like to speak in initials.  A plain English translation of the title of this piece would read “FDA ‘places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in Schedule V.’”  DEA Final Order, Docket No. DEA-486 Schedule V drugs include cough medicine with codeine and many pain relievers that still require a prescription.  So, really what this order does is allow doctors in the US legally to prescribe the recently approved epilepsy drug, Epidiolex, and allows pharmacies, rather than marijuana dispensaries, legally to sell the drug.
Continue Reading

On June 25, 2018, the Food and Drug Administration (“FDA”) approved Epidiolex (cannabidiol), the first marijuana derived drug for use in the United States, to treat two rare forms of epilepsy. This decision for the FDA could have sweeping effects for the marijuana industry. While the FDA has previously approved drugs comprising synthetic (manufactured) cannabinoids, this is the first FDA approved drug comprised of an active ingredient derived from marijuana. Even with FDA approval, further action is required before Epidiolex can enter the market in the United States.


Continue Reading